Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lung Neoplasms 10Burkitt Lymphoma 9Leukemia, Myeloid, Acute 8Lymphoma 7Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Sarcoma, Ewing 3Sarcoma 3Rhabdomyosarcoma 3Rhabdoid Tumor 3Retinoblastoma 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroblastoma 3Neoplasms, Germ Cell and Embryonal 3Myelodysplastic Syndromes 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Immunoblastic Lymphadenopathy 3Seminoma 2

Interventions

trastuzumab deruxtecan 1toripalimab 1pertuzumab 1pembrolizumab 1atezolizumab 1Trastuzumab 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Cancer × Etoposide × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡